Throughout most components of the particular world, the particular most well-known shape of motorized vehicle is a motor cycle likewise termed as motorbike. Simply because are generally affordable and likewise will be selected for a myriad of reasons, majority of the particular males would rather buy these motorcycles. Between the particular various types of cycles that are available today, the particular most favored ones are likely to be sport bikes which can be selected for sporting reasons. What makes most of these bikes stand out usually are their fairings. According to the specific automotive dictionary, motorcycle fairings are generally pretty much a shielding shell which is inserted over headlights and moreover different electric components of the particular bike. Primarily sports and in addition race bikes utilize most of these fairings.
Streamlining on motorbikes was actually completed initial within the early 1920?s costume however, the particular individuality suzuki fairings was actually given whenever they began to be chosen with regard to aircrafts. Due to the fact per studies, bike fairings strengthen the particular frontal area of the particular cycle by 5% with regard to assessment to a naked bike. Currently, a number of companies manufacture these fairings consequently persons will likely know Yamaha fairings, Honda fairings and in addition Suzuki fairings amongst others. Nevertheless, generally there are usually different types of motorcycle fairings that is found and in addition A single requirements to judge the specific kind of fairing they prefer before purchasing them.1st off, generally there is definitely full-body fairing which, because implies via the particular identification, means which each upper and in addition decrease portions of the particular motorbike are generally protected. The particular engine and in addition body will be protected by means of full motorcycle fairings inside the event of a collision. Instead of the particular motor cover, it can be your fairings which slide traveling. Hence, persons will almost certainly utilize Suzuki fairings to cover the bike particularly if maybe they ride at high speeds. Following, generally there is half-faring which extends below the specific handlebars, includes a dashboard or windscreen and in addition covers the specific cylinder box. 50 percent faired models come with fairing packages within the market which is to be selected to manufacture these people into full models. Fairing kits will be without difficulty purchased within the sell for installation reasons. The majority of the particular brands, regardless of whether perhaps they are generally Kawasaki Verkleidungenand or Yamaha fairings, create make use of of acrynlonitrile butadiene styrene (ABS) plastic-type for manufacturing your motorcycle fairings. This really is since its light weight and as well flexible. As well, with regards to the particular race monitor, mostly fiber window fairings are generally selected with motorcycles because they are typically light and in addition likewise durable. The actual most expensive material which is selected with regard to extreme activities is carbon-fiber-reinforced polymer. Us all can select the particular content for your own fairings and therefore buy fairing kits as a result.
For more information about fairings visit our website.
During this time many people are using green tea as a health drink. Apparently, according to research conducted by experts, for the health benefits of green tea is green much. Tea contain antioxidants that can resist the poison that will go into our bodies. Green tea also contains vitamin E and vitamin C are beneficial for strengthening the immune system, healthy skin and hair health.
In Green tea contains compounds called polyphenols, which are very much a role as a protector against cancer. Polyphenols belong to a very potent antioxidant. This compound will neutralize free radicals that cause cancer.
Their own free radicals created naturally in the body. These molecules can damage human cells. People suspect that this is one of the molecular causes of cancer, including various kinds of other diseases such as heart disease and aging.
Green tea leaves that have dried consists of 40% polyphenols. In addition to fighting breast cancer, these substances are also believed to reduce the risk of gastric cancer, lung, colon, rectum, liver, and pancreas.
Benefits of Green Tea, among others, is as an antioxidant, repairing damaged cells, smooth skin, slim body, prevent cancer, prevent heart disease, reduce cholesterol in the blood, the blood circulation. So, do not be surprised if the drink is touted as a beverage rich in benefits.
There is also a need to consider when you are drinking tea for a useful substance in the body are missing, among others:
Do not drink tea during or after meals because they contained a substance in food can be stolen by stimulants tea.
Do not drink tea on an empty stomach because it can increase stomach acid production.
Avoid drinking tea laced with sugar because it causes the substances they contain to be reduced.
Do not drink tea that had been all night because it was a lot of substances are oxidized and stale so the impact is not good for the body.
Avoid drinking tea during pregnancy and lactation. Due to the stimulants caffeine and tea can stimulate uterine contractions. In addition to nursing mothers would interfere with the production of milk-producing glands of the mother, or breastmilk.
GREEN TEA efficacy Properties include: Health properties of tea have been known for thousands of years ago. In scientific research, discovered tea as pharmacology uses for the human body. Due to the different types of chemical compounds such as amino acids, pure alkaloids, aromatic substances and vitamins.
Vitamin C content in tea is higher than the existing content in apples, tomatoes and lime juice. While the B12 magnitude 10-20 times higher than that obtained in cereals and vegetables, and components are not readily available in other foods.
Tea contains amino acids needed by the body, rich in minerals and various vitamins. A tea drinker who regularly drank tea with a dose of rational, will get a regular supply of nutrients for the body and cause the formation of natural immunity.
From the results of research in the Soviet Union as well as green tea black tea, serves as one element that can help so as not susceptible to disease. Expert researchers from the Academy of Preventife Chinnese Medicine in China, after studying 17 types of tea can be proved that tea can slow the formation of nitrosamines in the body.
In addition, some elements in the tea can detect the development of tumor cells found in some parts of the human body.
Compounds in tea and its function: 1. Catechin
Lowering cholesterol levels Lowering blood pressure and blood sugar levels Anti-cancer, anti-mutant factor Helps the kidneys to prevent the occurrence of gallstones 2. Polyphenols / tannins
Improving digestion, dysentery bacteria killed Has the function of anti-oxidants Dissolve fat 3. Caffeine (Theophyiline Theobromine)
Stimulates the central nervous Improving blood circulation, helps kidney function Increase the concentration 4. OIL ESSENCE
Improving digestion and dissolves fat Source of tea aroma 5. Flavanols
Prevent and fight against influenza Reduce stress Lowering high blood pressure Has the function of anti-oxidants Protect the cornea and UV light (prevents cataracts) 8. VITAMIN E
Prevent premature aging Reduce the risk of heart disease and stroke Prevent the formation of fat in blood vessels 9. VITAMIN B COMPLEX
Helps carbohydrate metabolism 10. MONOCITRATE
Prevent bad breath (breath is not fresh) 11. CHLOROPIL
How to plaster the world, cheaply!Public release date: 5-Apr-2012 [ | E-mail | Share ]
Contact: Richard Mellor r.d.mellor@leeds.ac.uk 44-113-343-4031 University of Leeds
Scientists have discovered the initial stages by which gypsum crystals form.
Gypsum is a naturally occurring mineral which is often used in industrial processes and which in nature, if left alone for thousands of years, can grow into huge translucent, towering and eerie, crystals more than 10 metres tall. These are famed for their beauty in places such as the Cave of Crystals in Mexico. Nevertheless, the formation of gypsum has until now been largely unexplored.
A study by researchers from the School of Earth and Environment at the University of Leeds and the Laboratorio de Estudios Cristalogrficos CSIC-University of Granada found that gypsum starts off as tiny crystals of a mineral called bassanite. Most of us know this as Plaster of Paris as we use it in building, art-work, casts and fireproofing. Currently bassanite plaster is manufactured at a rate of 100 million tons per year by dehydrating quarried gypsum at 150 deg C. Builders, artists and medical specialists buy the bassanite powder and add water to create a malleable material that hardens once dried again.
By experimenting with supersaturated gypsum solutions, the researchers were able to produce bassanite at room temperature. This than transforms to gypsum.
Professor Liane G Benning from the University of Leeds said: "This process has never been documented before. In nature gypsum grows as these fantastic large crystals, yet we show that in the lab gypsum actually grows through the assembly of many, tiny bassanite crystals. These link together like a string of pearls before they crystallize to gypsum. We studied hundreds of high-resolution images and caught the tiny bassanite crystals in the act of assembling into gypsum"
Their findings are published today (April 6) in the journal Science.
The lead author, Alexander van Driessche from the Laboratorio de Estudios Cristalogrficos in Grenada said: "Our study shows a new, low cost and low temperature way of making bassanite, although so far we have only managed to keep it stable for up to one hour."
This finding may also be applicable for reducing the clogging of pipes and filters through the precipitation of gypsum during water desalination or oil production. It can cost millions of pounds to remove gypsum from a pipe a serious economic problem specifically for countries supplying much needed drinking water.
Prof. Juan Manuel Garcia Ruiz, the director of the Laboratorio de Estudios Cristalogrficos in Granada said: "The study reveals how a natural mineral forming process can have important economic consequences for our daily lives. It also tells us how nature can make such beautiful and enormous crystals as seen in the caves at Naica or even the gypsum and bassanite, recently documented on Mars".
Finally, Prof. Benning said" If we manage to produce and stabilize bassanite crystals at room temperature through a clean, green method for long periods, we don't just learn something about a natural process but, compared to what is industry standard currently, our research could also lead to a massive cost and energy saving for the production of plaster".
###
The UK-Spanish study was funded by the Marie Curie EU-FP6 Mineral Nucleation and Growth Kinetics (MIN-GRO) Research and Training Network (contract MRTNCT-2006-035488), the School of Earth and Environment at the University of Leeds, and the Ministerio de Economia y Competitividad: Project Factora de Cristalizacin.
The role and implications of bassanite as a stable precursor phase to gypsum precipitation by A.E.S. Van Driessche, L.G. Benning, J.D. Rodriguez-Blanco, M. Ossorio, P. Bots and J.M. Garcia-Ruiz is published in Science on April 6, 2012. Media can obtain copies of the study by emailing Science at scipak@aaas.org.
For further information
To request an interview please contact
Richard Mellor, University of Leeds Press Office +44 (0)113 3434031 r.d.mellor@leeds.ac.uk
Further information about the Leeds group: http://homepages.see.leeds.ac.uk/~earlgb/
Alexander van Driessche, Postdoctoral fellow, Laboratorio de Estudios Cristalogrficos, CSIC-University of Granada T: +34 958230000 ext 190109; E: sander@lec.csic.es;
Juan Manuel Garcia-Ruiz is the Director of the Laboratorio de Estudios Cristalogrficos, CSIC-University of Granada T:+34 958230000 ext 190109; E: jmgruiz@ugr.es website: http://garciaruiz.com/JuanMa.html
A photo-composite is available to media at http://goo.gl/U6Njm showing at left giant gypsum crystals up to 11 metres long in the Cave of Crystals, Naica, Chihuahua, Mexico (photo must be credited to Javier Trueba) and at right tiny assembled bassanite nanoscrystals just before they transform to gypsum as produced by the researchers in the lab (high-resolution microphotograph must be credited to Liane G. Benning, University of Leeds).
Notes to editors
The 2008 Research Assessment Exercise showed the University of Leeds to be the UK's eighth biggest research powerhouse. The University is one of the largest higher education institutions in the UK and a member of the Russell Group of research-intensive universities. The University's vision is to secure a place among the world's top 50 by 2015. www.leeds.ac.uk
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
How to plaster the world, cheaply!Public release date: 5-Apr-2012 [ | E-mail | Share ]
Contact: Richard Mellor r.d.mellor@leeds.ac.uk 44-113-343-4031 University of Leeds
Scientists have discovered the initial stages by which gypsum crystals form.
Gypsum is a naturally occurring mineral which is often used in industrial processes and which in nature, if left alone for thousands of years, can grow into huge translucent, towering and eerie, crystals more than 10 metres tall. These are famed for their beauty in places such as the Cave of Crystals in Mexico. Nevertheless, the formation of gypsum has until now been largely unexplored.
A study by researchers from the School of Earth and Environment at the University of Leeds and the Laboratorio de Estudios Cristalogrficos CSIC-University of Granada found that gypsum starts off as tiny crystals of a mineral called bassanite. Most of us know this as Plaster of Paris as we use it in building, art-work, casts and fireproofing. Currently bassanite plaster is manufactured at a rate of 100 million tons per year by dehydrating quarried gypsum at 150 deg C. Builders, artists and medical specialists buy the bassanite powder and add water to create a malleable material that hardens once dried again.
By experimenting with supersaturated gypsum solutions, the researchers were able to produce bassanite at room temperature. This than transforms to gypsum.
Professor Liane G Benning from the University of Leeds said: "This process has never been documented before. In nature gypsum grows as these fantastic large crystals, yet we show that in the lab gypsum actually grows through the assembly of many, tiny bassanite crystals. These link together like a string of pearls before they crystallize to gypsum. We studied hundreds of high-resolution images and caught the tiny bassanite crystals in the act of assembling into gypsum"
Their findings are published today (April 6) in the journal Science.
The lead author, Alexander van Driessche from the Laboratorio de Estudios Cristalogrficos in Grenada said: "Our study shows a new, low cost and low temperature way of making bassanite, although so far we have only managed to keep it stable for up to one hour."
This finding may also be applicable for reducing the clogging of pipes and filters through the precipitation of gypsum during water desalination or oil production. It can cost millions of pounds to remove gypsum from a pipe a serious economic problem specifically for countries supplying much needed drinking water.
Prof. Juan Manuel Garcia Ruiz, the director of the Laboratorio de Estudios Cristalogrficos in Granada said: "The study reveals how a natural mineral forming process can have important economic consequences for our daily lives. It also tells us how nature can make such beautiful and enormous crystals as seen in the caves at Naica or even the gypsum and bassanite, recently documented on Mars".
Finally, Prof. Benning said" If we manage to produce and stabilize bassanite crystals at room temperature through a clean, green method for long periods, we don't just learn something about a natural process but, compared to what is industry standard currently, our research could also lead to a massive cost and energy saving for the production of plaster".
###
The UK-Spanish study was funded by the Marie Curie EU-FP6 Mineral Nucleation and Growth Kinetics (MIN-GRO) Research and Training Network (contract MRTNCT-2006-035488), the School of Earth and Environment at the University of Leeds, and the Ministerio de Economia y Competitividad: Project Factora de Cristalizacin.
The role and implications of bassanite as a stable precursor phase to gypsum precipitation by A.E.S. Van Driessche, L.G. Benning, J.D. Rodriguez-Blanco, M. Ossorio, P. Bots and J.M. Garcia-Ruiz is published in Science on April 6, 2012. Media can obtain copies of the study by emailing Science at scipak@aaas.org.
For further information
To request an interview please contact
Richard Mellor, University of Leeds Press Office +44 (0)113 3434031 r.d.mellor@leeds.ac.uk
Further information about the Leeds group: http://homepages.see.leeds.ac.uk/~earlgb/
Alexander van Driessche, Postdoctoral fellow, Laboratorio de Estudios Cristalogrficos, CSIC-University of Granada T: +34 958230000 ext 190109; E: sander@lec.csic.es;
Juan Manuel Garcia-Ruiz is the Director of the Laboratorio de Estudios Cristalogrficos, CSIC-University of Granada T:+34 958230000 ext 190109; E: jmgruiz@ugr.es website: http://garciaruiz.com/JuanMa.html
A photo-composite is available to media at http://goo.gl/U6Njm showing at left giant gypsum crystals up to 11 metres long in the Cave of Crystals, Naica, Chihuahua, Mexico (photo must be credited to Javier Trueba) and at right tiny assembled bassanite nanoscrystals just before they transform to gypsum as produced by the researchers in the lab (high-resolution microphotograph must be credited to Liane G. Benning, University of Leeds).
Notes to editors
The 2008 Research Assessment Exercise showed the University of Leeds to be the UK's eighth biggest research powerhouse. The University is one of the largest higher education institutions in the UK and a member of the Russell Group of research-intensive universities. The University's vision is to secure a place among the world's top 50 by 2015. www.leeds.ac.uk
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Remember that whole complicated father-son dynamic from the original "Star Wars" movies? Well, a new children's book prefers Luke and Darth to just eat ice cream instead. Also, here's a picture from the "Riddick" set, but Vin Diesel appears to be missing. Find out more about all that cool stuff, plus you can learn all [...]
FILE - This is a Sunday July 10, 2011 photo of then Chief executive of News Corporation Europe and Asia, James Murdoch gesturing as he leaves his father Chairman of News Corporation Rupert Murdoch's residence, in central London. Britain's Sky News says media executive James Murdoch, under pressure over his role in Britain's tabloid phone hacking scandal, is stepping down as chairman of British Sky Broadcasting. Sky, the news channel of BSkyB, reports that the resignation will be confirmed later Tuesday April 3, 2012 after a board meeting. (AP Photo/Sang Tan, File)
FILE - This is a Sunday July 10, 2011 photo of then Chief executive of News Corporation Europe and Asia, James Murdoch gesturing as he leaves his father Chairman of News Corporation Rupert Murdoch's residence, in central London. Britain's Sky News says media executive James Murdoch, under pressure over his role in Britain's tabloid phone hacking scandal, is stepping down as chairman of British Sky Broadcasting. Sky, the news channel of BSkyB, reports that the resignation will be confirmed later Tuesday April 3, 2012 after a board meeting. (AP Photo/Sang Tan, File)
This is a Nov 2011 image released by BSKYB PLC. on Tuesday April 3, 2012 of the company new chairman Nicholas Ferguson. Media executive James Murdoch, under pressure over his role in Britain's tabloid phone hacking scandal, has stepped down as chairman of British Sky Broadcasting PLC, the company announced Tuesday. BSkyB said he would be replaced as chairman by Nicholas Ferguson, the previous deputy chairman. Murdoch remains a member of the BSkyB board. (AP Photo/BSKYB PLC)
The entrance of one of the BSkyB headquarter buildings complex in west London, Tuesday, April 3, 2012. Media executive James Murdoch, under pressure over his role in Britain's tabloid phone hacking scandal, is stepping down as chairman of British Sky Broadcasting, the Sky News channel reported Tuesday, Sky, the news channel of BSkyB, said he resignation would be confirmed later Tuesday after an unscheduled board meeting. It said Murdoch would remain a board member and would be replaced as chairman by Nicholas Ferguson, the current deputy chairman. (AP Photo/Lefteris Pitarakis)
FILE - This is a Wednesday, March 23, 2011 file photo of James Murdoch, News Corp. chief executive of Europe and Asia, speaks during the inauguration of FICCI Frames in Mumbai, India. British Sky Broadcasting PLC said Tuesday April 3, 2012 that James Murdoch has stepped down as chairman, but will remain a member of the broadcaster's board. Murdoch is under pressure over his role in Britain's tabloid phone hacking scandal and said in a letter to the board Tuesday that he was resigning to that "the interests of BSkyB should not be undermined by matters outside the scope of this company." (AP Photo/Rafiq Maqbool. File)
FILE In this Tuesday, July 19, 2011 file photo Chief executive of News Corporation Europe and Asia, James Murdoch, arrives at the News International headquarters in London. Britain's Sky News says media executive James Murdoch, under pressure over his role in Britain's tabloid phone hacking scandal, is stepping down as chairman of British Sky Broadcasting. Sky, the news channel of BSkyB, reports that the resignation will be confirmed later Tuesday April 3, 2012 after a board meeting. (AP Photo/Sang Tan)
LONDON (AP) ? Once his father's heir apparent, James Murdoch stepped down Tuesday as chairman of British Sky Broadcasting, surrendering one of the biggest jobs in the Murdoch media empire in a bid to distance the broadcaster from a deepening phone hacking scandal.
James Murdoch's credibility and competence have come under severe questioning because of the phone hacking crisis and alleged bribery by British newspapers while he was in charge, and he faces further questioning in the scandal.
"I am aware that my role as chairman could become a lightning rod for BSkyB and I believe that my resignation will help to ensure that there is no false conflation with events at a separate organization," the 39-year-old Murdoch said.
Tuesday's announcement was just the latest in a string of setbacks for James Murdoch, who has been shedding titles since the scandal heated up.
At the end of February, he quit as chairman of News International, the company's troubled British newspaper subsidiary, a move cast as allowing Rupert Murdoch's younger son to focus on News Corp.'s extensive TV holdings. He has also stepped down from the boards of auctioneer Sotheby's and pharmaceutical firm GlaxoSmithKline PLC.
Nicholas Ferguson, formerly deputy chairman, moved up to replace the younger Murdoch as chairman at BSkyB. Tom Mockridge, who recently replaced James Murdoch at the helm of News International, gained a new title of deputy chairman of BSkyB.
James Murdoch retains his roles as deputy chief operating officer of News Corp. and chairman and CEO of the company's international division. He also remains on the BSkyB board as a non-executive member.
"James Murdoch is a very good TV man. I think people there will regret his passing," said Paul Connew, a media consultant and former tabloid editor. "The bigger question it raises is, where does this leave News Corp. in relation to BSkyB?"
The phone hacking scandal has already effectively killed a bid by News Corp. to take full control of BSkyB and raised questions about the Murdoch empire's fitness to control the satellite broadcaster through the 39 percent share it already holds.
The junior Murdoch's resignation comes a month after Britain's communications regulator, Ofcom, said it was monitoring the hacking and bribery investigation to be sure that BSkyB was "fit and proper" to hold a broadcasting license.
The "fit and proper" test looks at the conduct of individuals who control and manage the company.
James Murdoch's resignation could either pave the way for News Corp. to divest BSkyB or take another run at taking full control of it, said Todd Juenger, a New York-based media company analyst with Sanford C. Bernstein & Co.
But because there would likely be an uproar of opposition in Britain to the latter, the more likely reason was simply to remove the shadow cast by the younger Murdoch's troubles and allow the company to operate free from distractions.
"Because of some baggage attached to Mr. (James) Murdoch, that was harder to do with him in that role," Juenger said.
BSkyB shares were down as much as 1 percent Tuesday at 675.5 pence after its news channel, Sky News, was first to report Murdoch's departure. In New York, News Corp. shares were down 3 cents at $19.89 in late afternoon trading.
More embarrassment could come later this month when the House of Commons Committee on Culture, Media and Sport is expected to publish its report on the phone hacking scandal. Both Murdochs are also likely to face a further appearance before a judge-led inquiry into phone hacking and journalism practices in general.
"How the mighty have fallen," said Chris Bryant, a British legislator who is among dozens of phone hacking victims who have won financial settlements from the Murdoch empire.
"Two years ago the Murdochs were courted by all and sundry, and now James Murdoch is running away with his tail between his legs."
At least 25 past and present employees of News International have been arrested in the police investigations of phone hacking, bribery and computer hacking. They include Rebekah Brooks, former chief executive of News International, and Andy Coulson, former editor of the now-defunct Sunday tabloid, News of the World.
The scandal has even embarrassed Prime Minister David Cameron, who hired Coulson as his director of communications and was a personal friend of Brooks.
Asked for his reaction to Murdoch's latest resignation, Cameron said: "Well, it's obviously a matter for him, and a matter for the company, and of course its shareholders."
James Murdoch was chairman of News International when the company settled two big phone hacking claims. Murdoch said he was unaware that hacking was widespread at the News of the World, which at the time blamed the problem on a single rogue reporter.
His father shut down the tabloid in July. Another Murdoch tabloid, The Sun, has also been at the center of the hacking scandal.
News International has settled about 60 lawsuits by phone-hacking targets, at a cost of millions of dollars (pounds). Some 60 more claims are being prepared.
When James Murdoch was re-elected chairman of BSkyB in November, 81 percent of shareholders supported him, a strong mark of disquiet given the near-unanimous votes accorded to other corporate chairs. A month earlier, he was re-elected to the News Corp. board, though 35 percent of the votes went against him, another noticeable stirring of discontent.
Despite Tuesday's resignation, the younger Murdoch appeared to still have the support of his father, who controls News Corp. through a family trust that will one day come under the command of his four oldest children, including James.
In a statement, Rupert Murdoch and Chief Operating Officer Chase Carey said they were "grateful" for James Murdoch's leadership of BSkyB and looked forward to his "continued substantial contributions at News Corp."
Some said Tuesday's resignation was not a surprise.
"I had expected actually that he would have stepped down at the time it was announced he was returning to New York and it is perhaps surprising that it has taken this long," said John Whittingdale, the Culture, Media and Sport chairman.
___
Business Writer Ryan Nakashima in Los Angeles contributed to this report.
BIND presents late-breaker clinical data at AACR on BIND-014's promising antitumor effectsPublic release date: 4-Apr-2012 [ | E-mail | Share ]
Contact: Kathryn Morris kathryn@theyatesnetwork.com 914-204-6412 The Yates Network
Data indicative of targeting ability of BIND-014 for high tumor drug concentration
Cambridge, MA BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted therapeutics called AccurinsTM, announced today the presentation of late-breaker clinical data for BIND-014, the lead drug candidate within a new class of targeted therapeutics that are programmed to concentrate at tumors, at the American Association for Cancer Research (AACR) 2012 Annual Meeting. BIND presented data from the ongoing Phase 1 clinical study of BIND-014, its targeted docetaxel Accurin, in patients with solid tumors that strongly translated from preclinical data, demonstrated safety and tolerability, and showed evidence of anti-tumor activity with six of 17 patients with advanced or metastatic solid tumor cancers. The preliminary Phase 1 data demonstrated partial response or stable disease in this heavily pretreated patient population with durable responses of up to six months in some cases. In addition, BIND-014 demonstrated evidence of anti-tumor activity in tumors for which conventional docetaxel is known to have minimal activity.
BIND-014 represents the first targeted and programmable Accurin nanomedicine to reach the clinic from BIND's proprietary drug development platform that creates targeted therapeutics designed to accumulate at the site of disease for high drug concentration and maximum therapeutic effect. BIND-014 employs a combination of a targeted biodegradable nanoparticle and docetaxel, a proven cancer drug. The ongoing Phase 1 study has reached a dose of 75 mg/m2 with dose escalation continuing and BIND-014 continues to be well-tolerated in the study.
"The early clinical activity observed with BIND-014 in patients with advanced or metastatic solid tumor cancers is encouraging," commented Daniel D. Von Hoff, M.D., F.A.C.P., Principal Investigator for the study and Physician-in-Chief and Distinguished Professor at the Translational Genomics Research Institute (TGen) and Chief Scientific Officer for US Oncology and the Scottsdale Clinical Research Institute. "There is a critical need for targeted treatment options for patients with difficult to treat solid tumors and we look forward to further evaluating the potential of BIND-014."
"The emerging BIND-014 clinical data are showing exciting signals of activity, validating the potential for the revolutionary impact of nanomedicines for the treatment of cancer," commented Philip W. Kantoff, MD, Chief Clinical Research Officer, Dana-Farber Cancer Institute, and Professor of Medicine, Harvard Medical School. "What's equally exciting is that I have never witnessed a potentially revolutionary technology go from concept to human clinical testing as rapidly as BIND-014, and this is credit to the world-class team of scientists, engineers, physicians, for-profit and non-profit organizations that have converged to advance this technology."
In a late-breaking poster presentation entitled "A Phase 1, Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of BIND-014 Given by IV Infusion to Patients with Advanced or Metastatic Cancer," BIND presented clinical data consistent with preclinical observations in which drug concentration at the tumor site and efficacy in multiple tumor types was demonstrated:
Preliminary evidence of anti-tumor activity during dose escalation with evidence of anti-tumor activity in six of the 17 patients treated ranging from one durable confirmed partial response (cervical cancer) and five with stabilization of disease (pancreatic, colorectal, bile duct, tonsillar and anal cancer).
Evidence of antitumor activity in cancers in which conventional docetaxel has minimal activity.
At all dose levels studied, with 75 mg/m2 reached to date, BIND-014 was generally well-tolerated with no new toxicities observed. Dose escalation continues.
Strong translation of pharmacokinetic data from preclinical findings to Phase 1 clinical data with highly differentiated PK profile from conventional docetaxel and strong dose linearity across doses. The clinical results are consistent with the preclinical findings that BIND-014 concentrates drug activity in the tumor resulting in improved efficacy.
"We are very pleased with these data as our ongoing clinical study with BIND-014 lays a strong foundation to advance into Phase 2 development later this year. In addition, these data show the emerging potential of BIND-014 to be a significant new cancer therapy for patients by fundamentally changing the pharmacology of docetaxel allowing it to differentially concentrate in the tumors by up to ten-fold, as shown in our preclinical models, for better clinical efficacy across multiple cancers including those in which conventional docetaxel has minimal activity," said Scott Minick, President and Chief Executive Officer of BIND Biosciences. "BIND-014 is the clinical validation of BIND's Accurin technology platform, and marks an important milestone for the field of nanomedicine, BIND and, most importantly, patients."
The Phase 1 study has an ascending, intravenous dose design. The objectives of the study are to determine the safety, tolerability and maximum tolerated dose of BIND-014 and to assess preliminary evidence of antitumor activity. This clinical study is being conducted at the Virginia G. Piper Cancer Center at Scottsdale Healthcare in Scottsdale, Arizona, in collaboration with the Translational Genomics Research Institute and the Scottsdale Healthcare Research Institute, the Karmanos Cancer Institute in Detroit, Michigan, and Marin Specialty Care in Greenbrae, California.
About BIND-014
BIND-014 is a programmable nanomedicine that combines a targeting ligand and a therapeutic nanoparticle. BIND-014 contains docetaxel, a proven cancer drug which is approved in major cancer indications including breast, prostate and lung, encapsulated in FDA-approved biocompatible and biodegradable polymers. BIND-014 is targeted to prostate specific membrane antigen (PSMA), a cell surface antigen abundantly expressed on the surface of cancer cells and on new blood vessels that feed a wide array of solid tumors. In preclinical cancer models,
BIND-014 was shown to deliver up to ten-fold more docetaxel to tumors than an equivalent dose of conventional docetaxel. The increased accumulation of docetaxel at the site of disease translated to marked improvements in antitumor activity and tolerability. BIND-014 is currently in Phase 1 human clinical testing in cancer patients with advanced or metastatic solid tumor cancers (NCT01300533). The early development of BIND-014 was funded in part by the National Cancer Institute and the U.S. National Institutes of Standards and Technology (NIST) under its Advanced Technology Program (ATP).
###
About BIND Biosciences
BIND Biosciences is a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM. BIND's Medicinal NanoengineeringTM platform enables the design, engineering and manufacturing of Accurins with unprecedented control over drug properties to maximize trafficking to disease sites, dramatically enhancing efficacy while minimizing toxicities.
BIND is developing a pipeline of novel Accurins that hold extraordinary potential to become best-in-class drugs and improve patient outcomes in the areas of oncology, inflammatory diseases and cardiovascular disorders. BIND's lead product candidate, BIND-014, is currently in Phase 1 clinical testing in cancer patients and is designed to selectively target a surface protein upregulated in a broad range of solid tumors. BIND also develops Accurins in collaboration with pharmaceutical and biotechnology partners to enable promising pipeline candidates to achieve their full potential and to utilize selective targeting to transform the performance of important existing drug products.
BIND is backed by leading investors, Polaris Venture Partners, Flagship Ventures, ARCH Venture Partners, NanoDimension, DHK Investments, EndeavourVision and Rusnano. BIND was founded on proprietary technology from the laboratories of two leaders in the field of nanomedicine, Professors Robert Langer, Sc.D., David H. Koch Institute Professor of the Massachusetts Institute of Technology (MIT) and Omid Farokhzad, M.D., Associate Professor of Harvard Medical School. For more information, please visit the company's web site at www.bindbio.com.
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
BIND presents late-breaker clinical data at AACR on BIND-014's promising antitumor effectsPublic release date: 4-Apr-2012 [ | E-mail | Share ]
Contact: Kathryn Morris kathryn@theyatesnetwork.com 914-204-6412 The Yates Network
Data indicative of targeting ability of BIND-014 for high tumor drug concentration
Cambridge, MA BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted therapeutics called AccurinsTM, announced today the presentation of late-breaker clinical data for BIND-014, the lead drug candidate within a new class of targeted therapeutics that are programmed to concentrate at tumors, at the American Association for Cancer Research (AACR) 2012 Annual Meeting. BIND presented data from the ongoing Phase 1 clinical study of BIND-014, its targeted docetaxel Accurin, in patients with solid tumors that strongly translated from preclinical data, demonstrated safety and tolerability, and showed evidence of anti-tumor activity with six of 17 patients with advanced or metastatic solid tumor cancers. The preliminary Phase 1 data demonstrated partial response or stable disease in this heavily pretreated patient population with durable responses of up to six months in some cases. In addition, BIND-014 demonstrated evidence of anti-tumor activity in tumors for which conventional docetaxel is known to have minimal activity.
BIND-014 represents the first targeted and programmable Accurin nanomedicine to reach the clinic from BIND's proprietary drug development platform that creates targeted therapeutics designed to accumulate at the site of disease for high drug concentration and maximum therapeutic effect. BIND-014 employs a combination of a targeted biodegradable nanoparticle and docetaxel, a proven cancer drug. The ongoing Phase 1 study has reached a dose of 75 mg/m2 with dose escalation continuing and BIND-014 continues to be well-tolerated in the study.
"The early clinical activity observed with BIND-014 in patients with advanced or metastatic solid tumor cancers is encouraging," commented Daniel D. Von Hoff, M.D., F.A.C.P., Principal Investigator for the study and Physician-in-Chief and Distinguished Professor at the Translational Genomics Research Institute (TGen) and Chief Scientific Officer for US Oncology and the Scottsdale Clinical Research Institute. "There is a critical need for targeted treatment options for patients with difficult to treat solid tumors and we look forward to further evaluating the potential of BIND-014."
"The emerging BIND-014 clinical data are showing exciting signals of activity, validating the potential for the revolutionary impact of nanomedicines for the treatment of cancer," commented Philip W. Kantoff, MD, Chief Clinical Research Officer, Dana-Farber Cancer Institute, and Professor of Medicine, Harvard Medical School. "What's equally exciting is that I have never witnessed a potentially revolutionary technology go from concept to human clinical testing as rapidly as BIND-014, and this is credit to the world-class team of scientists, engineers, physicians, for-profit and non-profit organizations that have converged to advance this technology."
In a late-breaking poster presentation entitled "A Phase 1, Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of BIND-014 Given by IV Infusion to Patients with Advanced or Metastatic Cancer," BIND presented clinical data consistent with preclinical observations in which drug concentration at the tumor site and efficacy in multiple tumor types was demonstrated:
Preliminary evidence of anti-tumor activity during dose escalation with evidence of anti-tumor activity in six of the 17 patients treated ranging from one durable confirmed partial response (cervical cancer) and five with stabilization of disease (pancreatic, colorectal, bile duct, tonsillar and anal cancer).
Evidence of antitumor activity in cancers in which conventional docetaxel has minimal activity.
At all dose levels studied, with 75 mg/m2 reached to date, BIND-014 was generally well-tolerated with no new toxicities observed. Dose escalation continues.
Strong translation of pharmacokinetic data from preclinical findings to Phase 1 clinical data with highly differentiated PK profile from conventional docetaxel and strong dose linearity across doses. The clinical results are consistent with the preclinical findings that BIND-014 concentrates drug activity in the tumor resulting in improved efficacy.
"We are very pleased with these data as our ongoing clinical study with BIND-014 lays a strong foundation to advance into Phase 2 development later this year. In addition, these data show the emerging potential of BIND-014 to be a significant new cancer therapy for patients by fundamentally changing the pharmacology of docetaxel allowing it to differentially concentrate in the tumors by up to ten-fold, as shown in our preclinical models, for better clinical efficacy across multiple cancers including those in which conventional docetaxel has minimal activity," said Scott Minick, President and Chief Executive Officer of BIND Biosciences. "BIND-014 is the clinical validation of BIND's Accurin technology platform, and marks an important milestone for the field of nanomedicine, BIND and, most importantly, patients."
The Phase 1 study has an ascending, intravenous dose design. The objectives of the study are to determine the safety, tolerability and maximum tolerated dose of BIND-014 and to assess preliminary evidence of antitumor activity. This clinical study is being conducted at the Virginia G. Piper Cancer Center at Scottsdale Healthcare in Scottsdale, Arizona, in collaboration with the Translational Genomics Research Institute and the Scottsdale Healthcare Research Institute, the Karmanos Cancer Institute in Detroit, Michigan, and Marin Specialty Care in Greenbrae, California.
About BIND-014
BIND-014 is a programmable nanomedicine that combines a targeting ligand and a therapeutic nanoparticle. BIND-014 contains docetaxel, a proven cancer drug which is approved in major cancer indications including breast, prostate and lung, encapsulated in FDA-approved biocompatible and biodegradable polymers. BIND-014 is targeted to prostate specific membrane antigen (PSMA), a cell surface antigen abundantly expressed on the surface of cancer cells and on new blood vessels that feed a wide array of solid tumors. In preclinical cancer models,
BIND-014 was shown to deliver up to ten-fold more docetaxel to tumors than an equivalent dose of conventional docetaxel. The increased accumulation of docetaxel at the site of disease translated to marked improvements in antitumor activity and tolerability. BIND-014 is currently in Phase 1 human clinical testing in cancer patients with advanced or metastatic solid tumor cancers (NCT01300533). The early development of BIND-014 was funded in part by the National Cancer Institute and the U.S. National Institutes of Standards and Technology (NIST) under its Advanced Technology Program (ATP).
###
About BIND Biosciences
BIND Biosciences is a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM. BIND's Medicinal NanoengineeringTM platform enables the design, engineering and manufacturing of Accurins with unprecedented control over drug properties to maximize trafficking to disease sites, dramatically enhancing efficacy while minimizing toxicities.
BIND is developing a pipeline of novel Accurins that hold extraordinary potential to become best-in-class drugs and improve patient outcomes in the areas of oncology, inflammatory diseases and cardiovascular disorders. BIND's lead product candidate, BIND-014, is currently in Phase 1 clinical testing in cancer patients and is designed to selectively target a surface protein upregulated in a broad range of solid tumors. BIND also develops Accurins in collaboration with pharmaceutical and biotechnology partners to enable promising pipeline candidates to achieve their full potential and to utilize selective targeting to transform the performance of important existing drug products.
BIND is backed by leading investors, Polaris Venture Partners, Flagship Ventures, ARCH Venture Partners, NanoDimension, DHK Investments, EndeavourVision and Rusnano. BIND was founded on proprietary technology from the laboratories of two leaders in the field of nanomedicine, Professors Robert Langer, Sc.D., David H. Koch Institute Professor of the Massachusetts Institute of Technology (MIT) and Omid Farokhzad, M.D., Associate Professor of Harvard Medical School. For more information, please visit the company's web site at www.bindbio.com.
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
IntegraGen launches ARISk test, a genetic screening tool for autism in high-risk childrenPublic release date: 4-Apr-2012 [ | E-mail | Share ]
Contact: Jane E. Rubinstein jrubinstein@rubenstein.com 212-843-8287 IntegraGen
The ARISk test screens children in multiplex families as early as 6 months by looking at 65 genetic markers associated with autism, paving way for early intervention and best outcomes
Cambridge, MA (April 4, 2012)-- IntegraGen, Inc., a biotechnology company dedicated to molecular biomarker discovery, today announced the launch of the ARISk Risk Assessment Test, a gender specific, genetic screening test that looks at 65 genetic markers associated with Autism Spectrum Disorder (ASD). The test is designed to assess the risk of autism in children from multiplex familiessiblings of children with ASD who are 6 to 30 months of age. According to the Centers for Disease Control (CDC), the average age of diagnosis for ASD is 4.0 years, despite conclusive evidence that early intervention can significantly improve IQ scores, language and social skills, and ensure best possible outcomes.
The announcement was made by Dr. Bernard Courtieu, chairman and chief executive officer of IntegraGen, SA, who said the ARISk Test will only be available through medical professionals including pediatricians, developmental pediatricians, child neurologists and autism clinicians. "The CDC's latest prevalence finding show the rate of ASD is 1 in 88 children, 40 percent of whom are not diagnosed until the age of 4.5 years," says Mr. Courtieu, noting that the Modified Checklist for Autism in Toddlers (M-CHAT) screening tool recommended by the American Academy of Pediatrics is only valid for children at 16 months or older. "Our mission is to provide a reliable tool for early assessment of a child's risk for ASD. We are very excited to offer clinicians the ARISk Test in light of growing evidence that early assessment and intervention offer children with ASD the best chance to reach their full potential."
"We know genetics definitely plays a role, that ASD runs in families and that early diagnosis and intervention are vital in order to achieve the best outcomes," says autism expert Antonio Hardan, MD, a member of IntegraGen's advisory board. "As a clinician, identifying risks for autism is important since siblings have a higher chance to develop the disorder in comparison to the general population."
The ARISk Test is a multi-SNP (Single Nucleotide Polymorphism), gender-specific, genetic screening test that looks at 65 specific genetic markers, or SNPs, shown to be associated with ASD. Of the 65 SNPS, eight are associated with ASD in males and females, 29 in males only, and 28 in females only. With the latest national prevalence of ASD in boys at 1:54, ASD is greater than four times more likely to occur in males.
Many studies have demonstrated a strong genetic basis for ASD, which often runs in families. The average recurrence risk for siblings of children with ASD reaches 18.7% (25.9% for males and 9.5% for females). Recent studies of fraternal twins indicate that autism is highly inheritable, and studies which identified numerous genetic markers associated with autism demonstrate a complex inheritance pattern.
Until now, genetic testing for ASD has primarily been limited to the identification of a number of specific copy number variants (CNVs). Chromosome microarray (CMA) tests detect the presence of rare CNVs at the chromosome level; but, autism-associated CNVs are found in approximately ten percent of children with ASD. Recently, a number of common genetic variants or SNPs have been shown to be related to the risk of ASD. While individual SNPs do not cause ASD, IntegraGen's rigorous studies have shown that the presence of a combination of autism-associated SNPs can predict with a high degree of certainty whether that child will develop ASD.
The ARISk Test has been developed and validated on two separate cohorts of almost 2,000 individuals with ASD. The Autism Speaks Autism Genetic Resource Exchange (AGRE) data base provided 545 families, including 964 siblings with ASD and 317 unaffected siblings; and the results were replicated in an independent data base including 627 families with 1,000 affected siblings and 288 unaffected siblings. IntegraGen has also initiated separate prospective clinical studies at the Cleveland Clinic and with clinicians at Cardinal Glennon Children's Medical Center, which is affiliated with St. Louis University. A test for children from families with no prior history of ASD is in development.
The ARISk Test is a laboratory developed test that is only available through licensed medical practitioners. DNA samples are collected via a simple cheek swab and sent to a CLIA-certified, CAP-accredited lab where the genetic markers are detected via state-of-the-art genomic testing instruments. Results are returned to the ordering physician two- to four-weeks after the sample is received. Children who are identified as having a significantly higher risk of developing autism have a two to four fold increased risk of autism compared to the average sibling of a child with autism. It is recommended that children who are identified as having a higher risk of autism be referred to an autism specialists for a diagnostic work-up and, if diagnosed, early behavioral intervention.
Since the test does not rule out ASD for children who are identified as having no change in risk or a decreased risk of autism, children who demonstrate signs of ASD should also be screened using the M-CHAT, a screening tool based on behavioral observation and designed to identify children who are candidates for referral to an autism specialist for diagnostic evaluation. The American Academy of Pediatrics recommends that all children be screened at 18 and 24 months of age.
###
About IntegraGen:
IntegraGen SA of Evry, France-based IntegraGen (ALINT.PA) is a biotechnology company dedicated to molecular biomarker discovery. The Company's wholly-owned US subsidiary is located in Cambridge, Massachusetts. The Company's goal is the development of molecular diagnostic products and services that provide clinicians with new tools to personalize diagnosis, treatment and therapy for complex debilitating diseases. Its Genetic Services Business provides state-of-the-art genotyping services to the research community. Focusing its efforts on the early identification of children at risk for autism spectrum disorder (ASD), IntegraGen has made inroads in identifying a number of common genetic variants associated with ASD.
Contact: Jane Rubinstein 212.843.8287; jrubinstein@rubenstein.com
Nadine Woloshin 212-843-8041; nwoloshin@rubenstein.com
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
IntegraGen launches ARISk test, a genetic screening tool for autism in high-risk childrenPublic release date: 4-Apr-2012 [ | E-mail | Share ]
Contact: Jane E. Rubinstein jrubinstein@rubenstein.com 212-843-8287 IntegraGen
The ARISk test screens children in multiplex families as early as 6 months by looking at 65 genetic markers associated with autism, paving way for early intervention and best outcomes
Cambridge, MA (April 4, 2012)-- IntegraGen, Inc., a biotechnology company dedicated to molecular biomarker discovery, today announced the launch of the ARISk Risk Assessment Test, a gender specific, genetic screening test that looks at 65 genetic markers associated with Autism Spectrum Disorder (ASD). The test is designed to assess the risk of autism in children from multiplex familiessiblings of children with ASD who are 6 to 30 months of age. According to the Centers for Disease Control (CDC), the average age of diagnosis for ASD is 4.0 years, despite conclusive evidence that early intervention can significantly improve IQ scores, language and social skills, and ensure best possible outcomes.
The announcement was made by Dr. Bernard Courtieu, chairman and chief executive officer of IntegraGen, SA, who said the ARISk Test will only be available through medical professionals including pediatricians, developmental pediatricians, child neurologists and autism clinicians. "The CDC's latest prevalence finding show the rate of ASD is 1 in 88 children, 40 percent of whom are not diagnosed until the age of 4.5 years," says Mr. Courtieu, noting that the Modified Checklist for Autism in Toddlers (M-CHAT) screening tool recommended by the American Academy of Pediatrics is only valid for children at 16 months or older. "Our mission is to provide a reliable tool for early assessment of a child's risk for ASD. We are very excited to offer clinicians the ARISk Test in light of growing evidence that early assessment and intervention offer children with ASD the best chance to reach their full potential."
"We know genetics definitely plays a role, that ASD runs in families and that early diagnosis and intervention are vital in order to achieve the best outcomes," says autism expert Antonio Hardan, MD, a member of IntegraGen's advisory board. "As a clinician, identifying risks for autism is important since siblings have a higher chance to develop the disorder in comparison to the general population."
The ARISk Test is a multi-SNP (Single Nucleotide Polymorphism), gender-specific, genetic screening test that looks at 65 specific genetic markers, or SNPs, shown to be associated with ASD. Of the 65 SNPS, eight are associated with ASD in males and females, 29 in males only, and 28 in females only. With the latest national prevalence of ASD in boys at 1:54, ASD is greater than four times more likely to occur in males.
Many studies have demonstrated a strong genetic basis for ASD, which often runs in families. The average recurrence risk for siblings of children with ASD reaches 18.7% (25.9% for males and 9.5% for females). Recent studies of fraternal twins indicate that autism is highly inheritable, and studies which identified numerous genetic markers associated with autism demonstrate a complex inheritance pattern.
Until now, genetic testing for ASD has primarily been limited to the identification of a number of specific copy number variants (CNVs). Chromosome microarray (CMA) tests detect the presence of rare CNVs at the chromosome level; but, autism-associated CNVs are found in approximately ten percent of children with ASD. Recently, a number of common genetic variants or SNPs have been shown to be related to the risk of ASD. While individual SNPs do not cause ASD, IntegraGen's rigorous studies have shown that the presence of a combination of autism-associated SNPs can predict with a high degree of certainty whether that child will develop ASD.
The ARISk Test has been developed and validated on two separate cohorts of almost 2,000 individuals with ASD. The Autism Speaks Autism Genetic Resource Exchange (AGRE) data base provided 545 families, including 964 siblings with ASD and 317 unaffected siblings; and the results were replicated in an independent data base including 627 families with 1,000 affected siblings and 288 unaffected siblings. IntegraGen has also initiated separate prospective clinical studies at the Cleveland Clinic and with clinicians at Cardinal Glennon Children's Medical Center, which is affiliated with St. Louis University. A test for children from families with no prior history of ASD is in development.
The ARISk Test is a laboratory developed test that is only available through licensed medical practitioners. DNA samples are collected via a simple cheek swab and sent to a CLIA-certified, CAP-accredited lab where the genetic markers are detected via state-of-the-art genomic testing instruments. Results are returned to the ordering physician two- to four-weeks after the sample is received. Children who are identified as having a significantly higher risk of developing autism have a two to four fold increased risk of autism compared to the average sibling of a child with autism. It is recommended that children who are identified as having a higher risk of autism be referred to an autism specialists for a diagnostic work-up and, if diagnosed, early behavioral intervention.
Since the test does not rule out ASD for children who are identified as having no change in risk or a decreased risk of autism, children who demonstrate signs of ASD should also be screened using the M-CHAT, a screening tool based on behavioral observation and designed to identify children who are candidates for referral to an autism specialist for diagnostic evaluation. The American Academy of Pediatrics recommends that all children be screened at 18 and 24 months of age.
###
About IntegraGen:
IntegraGen SA of Evry, France-based IntegraGen (ALINT.PA) is a biotechnology company dedicated to molecular biomarker discovery. The Company's wholly-owned US subsidiary is located in Cambridge, Massachusetts. The Company's goal is the development of molecular diagnostic products and services that provide clinicians with new tools to personalize diagnosis, treatment and therapy for complex debilitating diseases. Its Genetic Services Business provides state-of-the-art genotyping services to the research community. Focusing its efforts on the early identification of children at risk for autism spectrum disorder (ASD), IntegraGen has made inroads in identifying a number of common genetic variants associated with ASD.
Contact: Jane Rubinstein 212.843.8287; jrubinstein@rubenstein.com
Nadine Woloshin 212-843-8041; nwoloshin@rubenstein.com
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
![[ Back to EurekAlert! ]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_tPS5hVju6uAEMr3HtlMbXzJ6JMUDreZ3VNAHvy2x1Mv4L3Kppg_sv6fNT3nhBdiakmcRJrCz1GZKPSExE_BhIgOGwwR2bi0vLx9xg2IDQ=s0-d){kind=small}
Public release date: 5-Apr-2012
Share ]